chlorthalidone has been researched along with ramipril in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ljutic, D; Rumboldt, Z; Sardelic, S; Simunic, M | 1 |
| Ferdinand, KC | 1 |
| Armario, P; Banegas, JR; de la Cruz, JJ; de la Sierra, A; Gorostidi, M; Oliveras, A; Ruilope, LM; Segura, J; Vinyoles, E | 1 |
2 review(s) available for chlorthalidone and ramipril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recommendations for the management of special populations: racial and ethnic populations.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black or African American; Calcium Channel Blockers; Chlorthalidone; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Lisinopril; Male; Ramipril; Randomized Controlled Trials as Topic | 2003 |
1 trial(s) available for chlorthalidone and ramipril
| Article | Year |
|---|---|
Ramipril decreases chlorthalidone-induced loss of magnesium and potassium in hypertensive patients.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Chlorthalidone; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Magnesium; Male; Middle Aged; Potassium; Prospective Studies; Ramipril | 1995 |
3 other study(ies) available for chlorthalidone and ramipril
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Antihypertensive drug use in resistant and nonresistant hypertension and in controlled and uncontrolled resistant hypertension.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bisoprolol; Blood Pressure; Calcium Channel Blockers; Chlorthalidone; Diuretics; Drug Resistance; Drug Therapy, Combination; Humans; Hypertension; Imidazoles; Mineralocorticoid Receptor Antagonists; Ramipril; Tetrazoles | 2018 |